Methacholine challenge testing: Safety of low starting FEV1

Richard J. Martin; Jack S. Wanger; Charles G. Irvin; Becki Bucher Bartelson; Reuben M. Cherniack; Jeffrey M. Drazen; Elliot Israel; Stanley J. Szefler; Vernon M. Chinchilli; Elizabeth A. Manger; Robert F. Lemanske; Christine Sorkness; Jean G. Ford; Diane McLean; Samy Nochman; James E. Fish; Stephen P. Peters; Homer A. Bonshey; Steven C. Lazarus; John Fahy; Reuben R. Cherniack; Suzanne S. Hurd

doi:10.1378/chest.112.1.53

Methacholine challenge testing: Safety of low starting FEV₁

Richard J. Martin, Jack S. Wanger, Charles G. Irvin, Becki Bucher Bartelson, Reuben M. Cherniack, Jeffrey M. Drazen, Elliot Israel, Stanley J. Szefler, Vernon M. Chinchilli, Elizabeth A. Manger, Robert F. Lemanske, Christine Sorkness, Jean G. Ford, Diane McLean, Samy Nochman, James E. Fish, Stephen P. Peters, Homer A. Bonshey, Steven C. Lazarus, John FahyReuben R. Cherniack, Suzanne S. Hurd

Research output: Contribution to journal › Article › peer-review

28 Scopus citations

Abstract

Study objective: The lower limit for the baseline value to initiate methacholine bronchial hyperresponsiveness testing has not been well established. Recommendations have varied from > 1 L to above 80% of predicted. The objective was to determine if an FEV₁ <60% predicted was acceptable. Design: Retrospective analysis of challenges in 88 patients with a baseline FEV₁ of <60% predicted (mean=45.8%; range, 22 to 59%. Setting: Academic institutions. Results: There were only four individuals whose FEV₁ did not return to >90% of baseline following one poststudy β₂-agonist treatment. All four responded to a second treatment. There were no adverse sequelae following challenge in any individual. Neither age (up to 79 years) nor gender influenced outcome. Conclusions: In chronic moderate to severe asthma, it appears that bronchial hyperresponsiveness testing can be safely performed even in those patients with a low baseline FEV₁.

Original language	English (US)
Pages (from-to)	53-56
Number of pages	4
Journal	CHEST
Volume	112
Issue number	1
DOIs	https://doi.org/10.1378/chest.112.1.53
State	Published - 1997

All Science Journal Classification (ASJC) codes

Pulmonary and Respiratory Medicine
Critical Care and Intensive Care Medicine
Cardiology and Cardiovascular Medicine

Access to Document

10.1378/chest.112.1.53

Cite this

Martin, R. J., Wanger, J. S., Irvin, C. G., Bartelson, B. B., Cherniack, R. M., Drazen, J. M., Israel, E., Szefler, S. J., Chinchilli, V. M., Manger, E. A., Lemanske, R. F., Sorkness, C., Ford, J. G., McLean, D., Nochman, S., Fish, J. E., Peters, S. P., Bonshey, H. A., Lazarus, S. C., ... Hurd, S. S. (1997). Methacholine challenge testing: Safety of low starting FEV₁. CHEST, 112(1), 53-56. https://doi.org/10.1378/chest.112.1.53

@article{209a97d13cd54ecea3b4cf7f772b20b1,

title = "Methacholine challenge testing: Safety of low starting FEV1",

abstract = "Study objective: The lower limit for the baseline value to initiate methacholine bronchial hyperresponsiveness testing has not been well established. Recommendations have varied from > 1 L to above 80% of predicted. The objective was to determine if an FEV1 <60% predicted was acceptable. Design: Retrospective analysis of challenges in 88 patients with a baseline FEV1 of <60% predicted (mean=45.8%; range, 22 to 59%. Setting: Academic institutions. Results: There were only four individuals whose FEV1 did not return to >90% of baseline following one poststudy β2-agonist treatment. All four responded to a second treatment. There were no adverse sequelae following challenge in any individual. Neither age (up to 79 years) nor gender influenced outcome. Conclusions: In chronic moderate to severe asthma, it appears that bronchial hyperresponsiveness testing can be safely performed even in those patients with a low baseline FEV1.",

author = "Martin, {Richard J.} and Wanger, {Jack S.} and Irvin, {Charles G.} and Bartelson, {Becki Bucher} and Cherniack, {Reuben M.} and Drazen, {Jeffrey M.} and Elliot Israel and Szefler, {Stanley J.} and Chinchilli, {Vernon M.} and Manger, {Elizabeth A.} and Lemanske, {Robert F.} and Christine Sorkness and Ford, {Jean G.} and Diane McLean and Samy Nochman and Fish, {James E.} and Peters, {Stephen P.} and Bonshey, {Homer A.} and Lazarus, {Steven C.} and John Fahy and Cherniack, {Reuben R.} and Hurd, {Suzanne S.}",

year = "1997",

doi = "10.1378/chest.112.1.53",

language = "English (US)",

volume = "112",

pages = "53--56",

journal = "CHEST",

issn = "0012-3692",

publisher = "American College of Chest Physicians",

number = "1",

}

Martin, RJ, Wanger, JS, Irvin, CG, Bartelson, BB, Cherniack, RM, Drazen, JM, Israel, E, Szefler, SJ, Chinchilli, VM, Manger, EA, Lemanske, RF, Sorkness, C, Ford, JG, McLean, D, Nochman, S, Fish, JE, Peters, SP, Bonshey, HA, Lazarus, SC, Fahy, J, Cherniack, RR & Hurd, SS 1997, 'Methacholine challenge testing: Safety of low starting FEV₁', CHEST, vol. 112, no. 1, pp. 53-56. https://doi.org/10.1378/chest.112.1.53

TY - JOUR

T1 - Methacholine challenge testing

T2 - Safety of low starting FEV1

AU - Martin, Richard J.

AU - Wanger, Jack S.

AU - Irvin, Charles G.

AU - Bartelson, Becki Bucher

AU - Cherniack, Reuben M.

AU - Drazen, Jeffrey M.

AU - Israel, Elliot

AU - Szefler, Stanley J.

AU - Chinchilli, Vernon M.

AU - Manger, Elizabeth A.

AU - Lemanske, Robert F.

AU - Sorkness, Christine

AU - Ford, Jean G.

AU - McLean, Diane

AU - Nochman, Samy

AU - Fish, James E.

AU - Peters, Stephen P.

AU - Bonshey, Homer A.

AU - Lazarus, Steven C.

AU - Fahy, John

AU - Cherniack, Reuben R.

AU - Hurd, Suzanne S.

PY - 1997

Y1 - 1997

N2 - Study objective: The lower limit for the baseline value to initiate methacholine bronchial hyperresponsiveness testing has not been well established. Recommendations have varied from > 1 L to above 80% of predicted. The objective was to determine if an FEV1 <60% predicted was acceptable. Design: Retrospective analysis of challenges in 88 patients with a baseline FEV1 of <60% predicted (mean=45.8%; range, 22 to 59%. Setting: Academic institutions. Results: There were only four individuals whose FEV1 did not return to >90% of baseline following one poststudy β2-agonist treatment. All four responded to a second treatment. There were no adverse sequelae following challenge in any individual. Neither age (up to 79 years) nor gender influenced outcome. Conclusions: In chronic moderate to severe asthma, it appears that bronchial hyperresponsiveness testing can be safely performed even in those patients with a low baseline FEV1.

AB - Study objective: The lower limit for the baseline value to initiate methacholine bronchial hyperresponsiveness testing has not been well established. Recommendations have varied from > 1 L to above 80% of predicted. The objective was to determine if an FEV1 <60% predicted was acceptable. Design: Retrospective analysis of challenges in 88 patients with a baseline FEV1 of <60% predicted (mean=45.8%; range, 22 to 59%. Setting: Academic institutions. Results: There were only four individuals whose FEV1 did not return to >90% of baseline following one poststudy β2-agonist treatment. All four responded to a second treatment. There were no adverse sequelae following challenge in any individual. Neither age (up to 79 years) nor gender influenced outcome. Conclusions: In chronic moderate to severe asthma, it appears that bronchial hyperresponsiveness testing can be safely performed even in those patients with a low baseline FEV1.

UR - http://www.scopus.com/inward/record.url?scp=0030860757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030860757&partnerID=8YFLogxK

U2 - 10.1378/chest.112.1.53

DO - 10.1378/chest.112.1.53

M3 - Article

C2 - 9228357

AN - SCOPUS:0030860757

SN - 0012-3692

VL - 112

SP - 53

EP - 56

JO - CHEST

JF - CHEST

IS - 1

ER -

Methacholine challenge testing: Safety of low starting FEV₁

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this